US EditionPublished • loading... • Updated
KFF Report Shows Medicaid Spending on GLP-1 Diabetes and Weight Loss Drugs Reaches Billions Nationwide
Summary by James Moore
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
KFF Report Shows Medicaid Spending on GLP-1 Diabetes and Weight Loss Drugs Reaches Billions Nationwide
A comprehensive new analysis from the Kaiser Family Foundation reveals that Medicaid programs across the country are grappling with unprecedented spending on GLP-1 receptor agonists, the popular diabetes and weight loss medications that include brand names like Ozempic, Wegovy, and Mounjaro. KFF Analysis Highlights Medicaid Financial Pressures from High-Cost GLP-1 Medications The research shows that state Medicaid programs are facing mounting pr…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
